Abstract
Background
The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study tried to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database.
Methods
SEER database (2010–2013) has been accessed through SEER*Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions. Overall and lung cancer-specific survival analyses according to both 7th and 8th editions were conducted through Kaplan–Meier analysis and multivariate analysis was conducted through a Cox proportional hazard model.
Results
A total of 127,096 patients with NSCLC were identified in the period from 2010 to 2013. For overall survival assessment according to the 8th edition, P values for all pair-wise comparisons among different stages were significant (<0.0001) except for the comparisons between stage IB and IIA (P = 0.146); stage IIA and IIB (P = 0.165). For lung cancer-specific survival according to the 8th edition, P values for all pair-wise comparisons among different stages were significant (<0.001). Among patients with stage I disease, multivariate analysis for factors affecting overall and lung cancer-specific survival among patients with stage I disease was conducted. The following factors were associated with worse overall and lung cancer-specific survival: age ≥70 years, more advanced stage, male gender, squamous histology, no surgery and no radiotherapy (P < 0.0001 for all factors).
Conclusion
This SEER analysis supports the prognostic significance of the added sub-stages described within AJCC 8th edition stages I and III. Further work is needed to incorporate molecular markers and personalize the future editions of the AJCC staging system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Globocan.iarc.fr. Last Accessed on 27 Nov 2016.
Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, et al. Targeted therapy for localized non-small-cell lung cancer: a review. Onco Targets Ther. 2016;9:4099–104.
Abdel-Rahman O. Causes of death in long-term lung cancer survivors: a SEER database analysis. Curr Med Res Opin. 2017;. doi:10.1080/03007995.2017.1322052.
Abdel-Rahman O, Elhalawani H. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Futur Oncol. 2015;11(7):1109–22.
Sen F, Tambas M, Ozkaya K, Guveli ME, Ciftci R, Ozkan B, et al. Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy. Medicine. 2016;95(30):e4280.
Aggarwal C. Targeted therapy for lung cancer: present and future. Ann Palliat Med. 2014;3(3):229–35.
Bansal P, Rusthoven C, Boumber Y, Gan GN. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Futur Oncol. 2016;12(23):2713–27.
Groome PA, Bolejack V, Crowley JJ, Kennedy C, Krasnik M, Sobin LH, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):694–705.
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
Surveillance, epidemiology and end results Program. About the SEER Program. Available at http://seer.cancer.gov/about. Accessed 25 June 2016.
Ou SH, Zell JA. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California cancer registry. J Thorac Oncol. 2008;3(3):216–27.
Zell JA, Ignatius Ou SH, Ziogas A, Anton-Culver H. Validation of the proposed International Association for the Study of lung cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry. J Thorac Oncol. 2007;2(12):1078–85.
Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015;10(4):682–90.
Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R. Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J Thorac Oncol. 2012;7(10):1479–84.
Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7(33):53245–53.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The author declares that there is no conflict of interest.
Funding
This study was not funded.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
As this study is based on a publicly available database without identifying patient information, informed consent was not needed.
Rights and permissions
About this article
Cite this article
Abdel-Rahman, O. Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer. Clin Transl Oncol 19, 1414–1420 (2017). https://doi.org/10.1007/s12094-017-1673-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-017-1673-7